The Effectiveness of HESA-A Supplement Combined with Atorvastatin on Nonalcoholic Fatty Liver in Rats
سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 247
فایل این مقاله در 13 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_ZUMS-25-110_006
تاریخ نمایه سازی: 11 اردیبهشت 1400
چکیده مقاله:
Background and Objective: Fatty liver disease occurs due to disturbances in lipid metabolism (increased fat synthesis and halting of catabolism) which eventually leads to the accumulation of large amounts of fat (triglycerides) in liver cells, that if left untreated lead to inflammation and cirrhosis. This study aimed to investigate the effect of concomitant use of HESA-A and atorvastatin on biochemical parameters in non-alcoholic fatty liver disease compared with atorvastatin alone.
Methods and Materials: ۲۸ rats weighing ۱۸۰±۲۰ g were randomly divided into two groups: a control group (n = ۷) with standard diet and a HFD (high-fat diet) group (n=۲۱) which were fed for ۸ weeks. To confirm the induction of fatty liver; controls along with seven rats from the HFD group were killed. The remaining ۱۴ animals were divided into two groups. The first group received atorvastatin and the second group received HESA-A in combination with atorvastatin daily for ۳۰ days. Finally, biochemical parameters (glucose, lipid profile and liver enzymes) were measured and histological studies were performed on the liver samples.
Results: Biochemical parameters in the HESA-A combined with atorvastatin group were significantly decreased in comparison to the atorvastatin group (p<۰.۰۱). The histopathological study of liver tissue showed a significant reduction in the amount of fat tissue and conversion of fatty liver from grade ІІІ to grade І.
Conclusion: According to the results of this study, the use of HESA-A as a complementary treatment for fatty liver disease without side effects can be integral role in reducing the incidence of non-alcoholic fatty liver disease, especially in severe cases.
کلیدواژه ها:
نویسندگان
مجید عفتی
Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
محمود خرمی
Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
علی زارعی محمودی آبادی
Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
جواد رئوف سر شوری
Dept. of Anatomy, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :